Home > Research Team > Joan Seoane
Current positions
- Director of VHIO´s Translational Research Program
- Head of VHIO´s Gene Expression and Cancer Laboratory
- ICREA Research Professor, 2004
- Member of the Executive Board of VHIO
- Professor at the Universitat Autònoma de Barcelona
- Assistant Coordinator of the National Agency for Evaluation and Prospective Studies (ANEP)
- Member of the Executive Committee of the European Association for Cancer Research (EACR)
- Member of the Neuro-Oncology Committees of Vall d’Hebron University Hospital and scientific advisor for the Genome platform of the Vall d’Hebron Research Institute
- Member of the Spanish Society of Biochemistry and the European Association for Cancer Research
Email: jseoane(ELIMINAR)@vhio.net
Academic Qualifications
- Degree in Chemical Sciences from the University of Barcelona, 1993
- Doctorate in Biochemistry and Molecular Biology from the Universitat de Barcelona, 1998
- Icrea Research Professor, 2004
Areas of Research
- Study of the molecular mechanisms implicated in brain tumors
- Study of tumor stem cells
Prizes and Scholarships
- Memorial Sloan-Kettering Cancer Center Research Fellow (2003)
- Catalan Biology Society (Josep M. Sala Trepat) (2004)
- EMBO Young Investigator (2007)
- Banc de Sabadell Biomedical Research Prize (2009)
- Beckman-Coulter award of the Spanish Society of Biochemistry and Molecular Biology (2009)
- ERC, European Research Consortium
- Association for International Cancer Research (AICR)
- Ministry of Health (FIS- Instituto Carlos III)
- European Comission, Marie Curie International Reintegration Grant
- Ministry of Education and Science (FPU)
- British Royal Society
- Ministry of Education and Science (Foreign travel award)
- Ministry of Education and Science (FPI)
Most relevant scientific publications
- Eichhorn PJ, Rodón L, Gonzàlez-Juncà A, Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V, Prat A, Cuartas I, Jimenez J, García D, Sahuquillo J, Bernards R, Baselga J, Seoane J. USP15 stabilizes the TGF-beta receptor I and promotes oncogenesis through the activation of the TGF-beta signal in glioblastoma Nature Medicine in press 2012;
- Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, Rodón L, Folch G, Carmona MA, Prieto-Sánchez RM, Barba I, Martínez-Sáez E, Prudkin L, Cuartas I, Raventós C, Martínez-Ricarte F, Poca MA, García-Dorado D, Lahn MM, Yingling JM, Rodón J, Sahuquillo J, Baselga J, Seoane J. TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell 2010 Dec; 18(6): 655-68
- Peñuelas S, Anido J, Prieto-Sánchez RM, Folch G, Barba I, Cuartas I, García-Dorado D, Poca MA, Sahuquillo J, Baselga J, Seoane J. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 2009 Apr; 15(4): 315-27
- Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, Seoane J. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 2007 Feb; 11(2): 147-60
